Abbott Laboratories (ABT) P/E Ratio History
Historical price-to-earnings valuation from 1990 to 2025
Loading P/E history...
ABT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 6, 2026, Abbott Laboratories (ABT) trades at a price-to-earnings ratio of 11.3x, with a stock price of $86.25 and trailing twelve-month earnings per share of $7.99.
The current P/E is 61% below its 5-year average of 29.1x. Over the past five years, ABT's P/E has ranged from a low of 14.8x to a high of 43.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ABT trades at a 49% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
The PEG ratio of 0.38 (P/E divided by 134% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, ABT trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $99B | 21.5Lowest | - | +31% | |
| $83B | 28.9 | - | +55%Best | |
| $52B | 24.8 | 1.50 | -1% | |
| $48B | 45.5 | 6.42 | -74% | |
| $112B | 34.8 | 2.34 | +8% | |
| $124B | 34.7 | - | -5% | |
| $176B | 26.7 | 12.62 | +7% | |
| $30B | 22.5 | 0.56Best | +5% | |
| $17B | 30.5 | - | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ABT Historical P/E Data (1990–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $133.94 | $7.98 | 16.8x | -26% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $136.01 | $7.98 | 17.0x | -25% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $132.65 | $7.71 | 17.2x | -24% |
| FY2024 Q4 | $113.11 | $7.65 | 14.8x | -35% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $114.01 | $3.29 | 34.7x | +53% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $103.91 | $3.17 | 32.8x | +45% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $113.66 | $3.21 | 35.4x | +57% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $110.07 | $3.26 | 33.8x | +49% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $96.85 | $2.94 | 32.9x | +46% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $109.02 | $2.93 | 37.2x | +64% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $101.26 | $3.29 | 30.8x | +36% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $109.79 | $3.92 | 28.0x | +24% |
Average P/E for displayed period: 22.6x
Full ABT Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ABT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABT — Frequently Asked Questions
Quick answers to the most common questions about buying ABT stock.
Is ABT stock overvalued or undervalued?
ABT trades at 11.3x P/E, below its 5-year average of 29.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ABT's valuation compare to peers?
Abbott Laboratories P/E of 11.3x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is ABT's PEG ratio?
ABT PEG ratio is 0.38. Below 1.0 indicates valuation is supported by earnings growth rate. Historical P/E data spans 1990-2025.